<DOC>
	<DOCNO>NCT01237496</DOCNO>
	<brief_summary>This study evaluate immune response patient HBeAg-negative chronic Hepatitis B treat Pegasys ( peginterferon alfa-2a ) . Eligible patient randomize study ML18253 receive Pegasys 180 mcg subcutaneously 48 96 week . Sample collection period patient occur first 24 week .</brief_summary>
	<brief_title>Analysis HBV-Specific Immune Response Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys ( Peginterferon Alfa-2a ( 40KD ) ) - Immunology Sub-Study ML18253</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient 1855 year age Chronic HBeAg negative hepatitis B Liver disease consistent chronic hepatitis document liver biopsy within 18 month prior enrollment Participation study ML18253 . Interferonbased systemic antiHBV therapy &lt; /= 12 month prior first dose study drug Antiviral , antineoplastic , immunomodulatory treatment &lt; /= 12 month prior first dose study drug Nonresponders previous interferon therapy resistant lamivudine Coinfection hepatitis A , C D , human immunodeficiency virus ( HIV ) Hepatocellular cancer Compensated ( Child A , score 6 ) decompensated liver disease ( Child B C ) History evidence medical condition associate chronic liver disease HBV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>